Program
durvalumab
Also written as “Durvalumab”, “MEDI4736” and “MEDI4736 (Durvalumab)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Carcinoma, Hepatocellular · Urinary Bladder Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 8643 open or running | phase 4since May 27, 2020 | Sep 14, 2012 | Nov 30, 2026phase 2 · NCT07081633 |
| Bristol-Myers Squibb | 70 open or running | phase 2since Feb 16, 2016 | Nov 25, 2015 | none ahead |
| AbbVie | 20 open or running | phase 2since Feb 27, 2015 | Feb 27, 2015 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortium | 10 open or running | phase 2since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Advaxis | 10 open or running | phase 2since Nov 6, 2014 | Nov 6, 2014 | none ahead |
| AGO Research | 11 open or running | phase 2since Nov 11, 2020 | Nov 11, 2020 | Jan 2028phase 2 · NCT04644289 |
| Boston Scientific | 11 open or running | phase 2since Sep 1, 2021 | Sep 1, 2021 | Jun 2027phase 2 · NCT05063565 |
| Eli Lilly | 10 open or running | phase 1since Oct 7, 2015 | Oct 7, 2015 | none ahead |
Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited, biocompatibles-uk-ltd, Daiichi Sankyo, parexel, apices-soluciones-s-l, iqvia-pty-ltd, myriad-genetic-laboratories-inc, pra-health-sciences and Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Dec 15, 2016.
- May 22, 2023Phase 3 study in Liver NeoplasmsAstraZeneca · NCT05883644 · 111 enrolled · United States, France, Germany and more
- Jun 1, 2023Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT05924880 · 116 enrolled · China
- Jun 22, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05925530 · 142 enrolled · United States, Austria, Canada and more
- Jul 5, 2023Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsAstraZeneca · NCT05943106 · 100 enrolled · United States
- Aug 17, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06008093 · 103 enrolled · United States
- Sep 11, 2023Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT06040099 · 58 enrolled · United States
- Oct 23, 2023Phase 3 study in Breast NeoplasmsAstraZeneca · NCT06103864 · 625 planned · United States, Argentina, Australia and more
- Nov 28, 2024Phase 3 study in Endometrial NeoplasmsAstraZeneca · NCT06746116 · 45 enrolled · Spain
- Apr 29, 2025Phase 2 study in Urinary Bladder NeoplasmsAstraZeneca · NCT06960577 · 150 planned · Australia, Brazil, Canada and more
- May 12, 2025Phase 3 study in Small Cell Lung CarcinomaAstraZeneca · NCT06992609 · 71 enrolled · Spain
- Jun 23, 2025Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT07081633 · 114 enrolled · China, Hong Kong
- Jan 30, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT07391670 · 40 planned · Australia, Georgia, Poland and more
- Sep 15, 2026Phase 3 study in GastricAstraZeneca · NCT07877818 · 140 planned · China
- Oct 9, 2026Phase 4 study in Muscle-Invasive Bladder Cancer (MIBC)AstraZeneca · NCT07876817 · 50 planned
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT07081633
- Jun 2027Primary completion: phase 2 study in Carcinoma, HepatocellularBoston Scientific · NCT05063565
- Jun 30, 2027Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaAstraZeneca · NCT04550260
- Jul 28, 2027Primary completion: phase 3 study in Breast NeoplasmsAstraZeneca · NCT06103864
TargetBeta
“A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
The newest 60 of 100 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07876817Muscle-Invasive Bladder Cancer (MIBC) | 4 | Not yet recruiting | AstraZeneca | Jan 31, 2029 | 50 |
| NCT07877818Gastric · China | 3 | Recruiting | AstraZeneca | Nov 1, 2029 | 140 |
| NCT07391670Carcinoma, Non-Small-Cell Lung · Australia, Georgia, Poland and more | 1 | Recruiting | AstraZeneca | Aug 30, 2027 | 40 |
| NCT07081633Carcinoma, Hepatocellular · China, Hong Kong | 2 | Active, not recruiting | AstraZeneca | Nov 30, 2026 | 114 |
| NCT06992609Small Cell Lung Carcinoma · Spain | 3 | Active, not recruiting | AstraZeneca | Jun 30, 2029 | 71 |
| NCT06960577Urinary Bladder Neoplasms · Australia, Brazil, Canada and more | 2 | Recruiting | AstraZeneca | Aug 30, 2028 | 150 |
| NCT06746116Endometrial Neoplasms · Spain | 3 | Active, not recruiting | AstraZeneca | Nov 30, 2028 | 45 |
| NCT06103864Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Jul 28, 2027 | 625 |
| NCT06040099Carcinoma, Hepatocellular · United States | 2 | Active, not recruiting | AstraZeneca | Jun 30, 2026 | 58 |
| NCT06008093Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | AstraZeneca | Oct 27, 2026 | 103 |
| NCT05943106Non-Muscle Invasive Bladder Neoplasms · United States | 3 | Active, not recruiting | AstraZeneca | Jun 16, 2025 | 100 |
| NCT05925530Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | AstraZeneca | Jan 12, 2026 | 142 |
| NCT05924880Biliary Tract Neoplasms · China | 3 | Completed | AstraZeneca | Feb 7, 2025 | 116 |
| NCT05883644Liver Neoplasms · United States, France, Germany and more | 3 | Active, not recruiting | AstraZeneca | Mar 30, 2026 | 111 |
| NCT05771480Biliary Tract Neoplasms · United States, France, Germany and more | 3 | Active, not recruiting | AstraZeneca | Oct 2, 2025 | 142 |
| NCT05629585Breast Neoplasms · United States, Belgium, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Sep 1, 2027 | 1,174 |
| NCT05557838Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | AstraZeneca | Sep 30, 2026 | 214 |
| NCT05498155Breast Neoplasms · United States, Australia, Austria and more | 2 | Completed | AstraZeneca | Nov 20, 2024 | 50 |
| NCT05063565Carcinoma, Hepatocellular · United States, France, Italy and more | 2 | Active, not recruiting | Boston Scientific | Jun 2027 | 100 |
| NCT05043090Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Dec 31, 2025 | 148 |
| NCT04960709Urinary Bladder Neoplasms · United States, Argentina, Austria and more | 3 | Active, not recruiting | AstraZeneca | Mar 2, 2026 | 712 |
| NCT04870112Carcinoma, Non-Small-Cell Lung · United States, New Zealand, Spain and more | 1 | Terminated | AstraZeneca | Aug 30, 2023 | 18 |
| NCT04774380Small Cell Lung Carcinoma · Bulgaria, Canada, Czechia and more | 3 | Completed | AstraZeneca | Jun 12, 2023 | 152 |
| NCT04712903Small Cell Lung Carcinoma Extensive Disease · Spain | 3 | Completed | AstraZeneca | Jun 21, 2023 | 101 |
| NCT04644289Carcinoma, Ovarian Epithelial · Germany | 2 | Recruiting | AGO Research | Jan 2028 | 60 |
| NCT04642469Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | May 31, 2023 | 30 |
| NCT04550260Esophageal Squamous Cell Carcinoma · United States, Belgium, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Jun 30, 2027 | 640 |
| NCT04592913Gastrointestinal Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Dec 20, 2024 | 957 |
| NCT04416633Unresectable Non-small Cell Lung Cancer (NSCLC) · India | 4 | Completed | AstraZeneca | Oct 27, 2023 | 100 |
| NCT04449861Small Cell Lung Carcinoma Extensive Disease · China | 3 | Completed | AstraZeneca | Mar 30, 2023 | 166 |
| NCT04385368Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Aug 31, 2023 | 89 |
| NCT04269200Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jul 8, 2024 | 805 |
| NCT04249362Carcinoma, Non-Small-Cell Lung · United States, France, Italy and more | 2 | Completed | AstraZeneca | Mar 30, 2023 | 102 |
| NCT04145193Colonic Neoplasms | 2 | Withdrawn | AstraZeneca | Mar 19, 2024 | 0 |
| NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more | 2 | Active, not recruiting | AstraZeneca | May 6, 2025 | 247 |
| NCT03875235Biliary Tract Neoplasms · United States, Argentina, Bulgaria and more | 3 | Active, not recruiting | AstraZeneca | Aug 11, 2021 | 810 |
| NCT03847428Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | May 15, 2026 | 908 |
| NCT03833154Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Oct 31, 2028 | 724 |
| NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more | 1 | Active, not recruiting | AstraZeneca | May 23, 2023 | 175 |
| NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Completed | AstraZeneca | Jul 18, 2023 | 189 |
| NCT03794544Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Completed | AstraZeneca | Jan 13, 2021 | 84 |
| NCT03800134Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Active, not recruiting | AstraZeneca | Nov 10, 2022 | 825 |
| NCT03830866Locally Advanced Cervical Cancer · United States, Brazil, Chile and more | 3 | Completed | AstraZeneca | Jan 20, 2022 | 770 |
| NCT03778957Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Sep 11, 2023 | 724 |
| NCT03737643Ovarian Neoplasms · United States, Austria, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Mar 17, 2025 | 1,407 |
| NCT03732677Urinary Bladder Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Apr 29, 2024 | 1,063 |
| NCT03703297Small Cell Lung Carcinoma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jan 15, 2024 | 730 |
| NCT03693300Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 2 | Completed | AstraZeneca | Dec 13, 2022 | 117 |
| NCT03682068Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Jun 1, 2026 | 1,246 |
| NCT03706690Carcinoma, Non-Small-Cell Lung · China, Hong Kong, India and more | 3 | Active, not recruiting | AstraZeneca | Jun 23, 2024 | 407 |
| NCT03519971Carcinoma, Non-Small-Cell Lung · Brazil, Czechia, Hungary and more | 3 | Completed | AstraZeneca | Sep 7, 2023 | 328 |
| NCT03509012Squamous Cell Carcinoma of Head and Neck · United States, Japan, Korea, Republic of and more | 1 | Completed | AstraZeneca | Dec 31, 2020 | 105 |
| NCT03528694Non-Muscle Invasive Bladder Neoplasms · Australia, Austria, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Apr 3, 2025 | 1,018 |
| NCT03298451Carcinoma, Hepatocellular · United States, Brazil, Canada and more | 3 | Active, not recruiting | AstraZeneca | Aug 27, 2021 | 1,324 |
| NCT03164616Non Small Cell Lung Cancer NSCLC · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | AstraZeneca | Mar 12, 2021 | 1,186 |
| NCT03084471Diabetes Mellitus, Insulin-Dependent, 12 · United States, Canada, France and more | 3 | Completed | AstraZeneca | Mar 31, 2020 | 867 |
| NCT03043872Small Cell Lung Carcinoma · United States, Argentina, Austria and more | 3 | Active, not recruiting | AstraZeneca | Jan 27, 2020 | 987 |
| NCT03003520Lymphoma, Large B-Cell, Diffuse · United States, Austria, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Apr 24, 2022 | 46 |
| NCT03000452Multiple Myeloma · United States, Austria, Greece and more | 2 | Completed | Bristol-Myers Squibb | Sep 18, 2017 | 18 |
| NCT03003962Non Small Cell Lung Carcinoma NSCLC · United States, Australia, China and more | 3 | Active, not recruiting | AstraZeneca | Oct 27, 2022 | 669 |
How it is read
Names in the registry
- “Durvalumab”, 55 entries
- “MEDI4736”, 20 entries
- “durvalumab”, 7 entries
- “MEDI4736 (Durvalumab)”, 3 entries
- “MEDI4736 + tremelimumab”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 30 studies
- Small Cell Lung Carcinoma, 9 studies
- Carcinoma, Hepatocellular, 8 studies
- Urinary Bladder Neoplasms, 5 studies
- Squamous Cell Carcinoma of Head and Neck, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.